Anti-inflammatories in Alzheimer’s disease – potential therapy or spurious correlate? by Rivers-Auty, Jack et al.
1Anti-inflammatories in Alzheimer’s disease - potential therapy or spurious correlate? 
Jack Rivers-Auty1,2,3†, Alison E. Mather4,5, Ruth Peters6,7, Catherine B. Lawrence1,2, David Brough1,2.
Short title: NSAIDs in Alzheimer’s disease
*for the Alzheimer’s Disease Neuroimaging Initiative
*Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to 
the design and implementation of ADNI and/or provided data but did not participate in analysis or 
writing of this report. A complete listing of ADNI investigators can be found at: 
http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
1Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, 
Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, AV Hill 
Building, Oxford Road, Manchester, M13 9PT, U.K.
2Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester M13 
9PT, UK
3Medical Sciences, Tasmanian School of Medicine, College of Health and Medicine, University of 
Tasmania, Hobart, Tasmania, Australia
4Quadram Institute Bioscience, Norwich Research Park, Norwich, Norfolk, NR4 7UA, UK.
5University of East Anglia, Norwich Research Park, Norwich, Norfolk, NR4 7TJ, UK.
6School of Psychology, University of New South Wales, Sydney, NSW, Australia
7Neuroscience Research Australia, Barker Street, Sydney, New South Wales 2031, Australia
†to whom correspondence should be addressed: Jack Rivers-Auty. Tel: +61 (0)475 924 722; Fax: +44 161 
275 5948; Email: jack.auty@UTAS.edu.au, Post: 243-14 Medical Science Precinct, 2, Liverpool Street, 
University of Tasmania, Hobart, Tasmania, 7000, Australia
Search terms: Alzheimer’s disease, NSAID, inflammation, Cognitive decline
 
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
D
ow
nloaded from
 https://academ
ic.oup.com
/braincom
m
s/advance-article/doi/10.1093/braincom
m
s/fcaa109/5876020 by U
niversity of East Anglia user on 14 O
ctober 2020
2Keywords: Alzheimer’s disease, NSAID, inflammation, progression, anti-inflammatory
Abbreviations:
AD Alzheimer's disease
ADAS Alzheimer disease assessment scale
ADNI Alzheimer's disease neuroimaging initiative
AIC Akaike information criterion 
ApoE Apolipoprotein E
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3Abstract
Epidemiological evidence suggests non-steroidal anti-inflammatories (NSAIDs) reduce the risk of 
Alzheimer’s disease. However, clinical trials have found no evidence of NSAID efficacy. This 
incongruence may be due to the wrong NSAIDs being tested in robust clinical trials or the 
epidemiological findings being caused by confounding factors. Therefore, this study used logistic 
regression and the innovative approach of negative binomial generalised linear mixed modelling to 
investigate both prevalence and cognitive decline, respectively, in the Alzheimer’s Disease 
NeuroImaging dataset for each commonly used NSAID and paracetamol.
Use of most NSAIDs were associated with reduced Alzheimer’s disease prevalence yet no effect on 
cognitive decline was observed. Paracetamol had a similar effect on prevalence to these NSAIDs 
suggesting this association is independent of the anti-inflammatory effects and that previous results 
may be due to spurious associations. Interestingly, diclofenac use was significantly associated with both 
reduce incidence and slower cognitive decline warranting further research into the potential therapeutic 
effects of diclofenac in Alzheimer’s disease.
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4Introduction
Alzheimer’s disease (AD) is a debilitating age related dementia which is typified by initial loss of short 
term memory and spatial awareness, followed by mid and long term memory loss, confusion, 
personality changes, frailty, loss of motor function and death normally 5-7 years following initial 
diagnosis (Wattmo et al., 2014). AD is the most prevalent form of dementia, constituting 60-80% of 
dementia cases affecting an estimated 26 million people globally (Alzheimers Association, 2015). 
Because of the severe social and economic costs, AD has been the focus of extensive research yet the 
pathophysiology of AD remains poorly understood and disease modifying treatments continue to be 
elusive. However, the role of neuroinflammation as a key etiological feature is now widely accepted due 
the consensus of epidemiological, neuroimaging, preclinical and genetic evidence. Because of this, anti-
inflammatories have been thoroughly researched as putative disease modifying agents. 
Non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase (COX) enzymes and 
subsequent prostanoid production, are the most commonly used anti-inflammatory drugs with over 110 
million prescriptions annually in the USA alone (Conaghan, 2012). The prevalence of NSAIDs use makes 
them an ideal candidate for epidemiological investigations into the potential therapeutic effects of anti-
inflammatories in AD. Numerous epidemiological studies in a range of ethnodemographic populations 
have identified that NSAID use is associated with a lower risk of developing AD (Breitner et al., 1995, 
Cote et al., 2012, Fischer et al., 2008, in 't Veld et al., 2001, Landi et al., 2003, Stewart et al., 1997, 
Szekely et al., 2008, Vlad et al., 2008), and this association was suggested to be causal by numerous 
intervention based studies in animal models (Yan et al., 2003, Lim et al., 2000, Weggen et al., 2001). This 
led to a number of clinical trials of varying quality on NSAIDs and AD progression. Many of these trials 
were short term (6-12 months) and had low numbers of patients due to the lack of private funding 
available for existing drugs. Of the non-selective traditional NSAID clinical trials, Pasqualetti et al. 
performed the most extensive trial with 132 patients followed for 1 year. A total of 51 and 46 patients 
from the ibuprofen and placebo group completed the trial, respectively, and no differences in AD 
Assessment Scale (ADAS) or the Mini-Mental State Examination (MMSE) were observed between 
treatment groups (Pasqualetti et al., 2009). This is still a relatively small group of patients given the 
variability of the disease and relatively short period of observation. Larger trials have been performed 
with patented novel NSAIDs including trials of celecoxib with 425 subjects (Soininen et al., 2007), 
rofecoxib with 692 subjects (Reines et al., 2004); and tarenfluribil with 1684 subjects (Green et al., 
2009), all were conducted for at least one year and all demonstrated no significant effect of the NSAIDs 
on AD progression (Imbimbo et al., 2010). Several potential explanations for the discrepancy between 
the efficacy of NSAIDs in the epidemiological and clinical research fields have been put forward: (i) The 
NSAIDs effects seen in epidemiological research could be indirect through a hidden variable not 
investigated by the research. (ii) NSAIDs may require a long period of administration before they can 
provide a protective effect. This hypothesis is supported by epidemiological evidence; Stewart et al. 
(1997) analysed a longitudinal cohort study of 1686 elderly individuals and found that the risk of AD was 
only significantly decreased after more than two years of NSAID usage. (iii) The clinical trials 
methodology were not optimized for the treatments in that they should have: only included early AD or 
Mild Cognitively Impaired (MCI) individuals with confirmed amyloid positivity and neuroinflammation 
through PET imaging, had larger numbers, and a longer period of treatment (Stewart et al., 1997, 
Szekely & Zandi, 2010, Wyss-Coray, 2006). (iv) The NSAIDs selected for the high quality clinical trials 
were chosen for the novelty and patentability of the drugs; as these drugs were not the focus of the 
epidemiological or preclinical research it possible that there are different therapeutic profiles of 
https://mc.manuscriptcentral.com/braincom
D
ow
nloaded from
 https://academ
ic.oup.com
/braincom
m
s/advance-article/doi/10.1093/braincom
m
s/fcaa109/5876020 by U
niversity of East Anglia user on 14 O
ctober 2020
5traditional NSAIDs and potentially the dominant mechanisms of action is independent of COX inhibition 
(Stewart et al., 1997, Szekely & Zandi, 2010, Wyss-Coray, 2006). (v) While NSAIDs may reduce the risk of 
developing AD, they do not slow the progression of the disease; suggesting that NSAIDs act on initiating 
pathological processes of the disease not the downstream cascade of propagating mechanisms. The 
latter two of these explanations (iv & v) are addressed in the present study by investigating the 
association of individual NSAID use and cognitive decline (as opposed to incidence/prevalence) in MCI 
and AD subjects, as measured by the MMSE and ADAS scores, in the Alzheimer’s disease Neuroimaging 
Initiative (ADNI) case controlled longitudinal study dataset. From this it was found that most NSAIDs 
were not associated with any change in cognitive decline including celecoxib, aspirin, ibuprofen and 
naproxen. However, there was evidence that diclofenac was associated with slower cognitive decline. 
Though not technically an NSAID, paracetamol (acetaminophen) was included in the analysis as a 
common pain reliever which has indication overlap with NSAIDs and little mechanistic overlap. 
Interestingly, paracetamol use was associated with accelerated cognitive decline. Collectively this study 
concludes that the majority of NSAIDs do not affect the propagating mechanisms of AD and that the 
therapeutic potential of a subset of NSAIDs including diclofenac is likely to be independent of COX 
inhibition. 
Methods
Data acquisition
Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private 
partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to 
test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other 
biological markers, and clinical and neuropsychological assessment can be combined to measure the 
progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD).The subjects were 
recruited from over 50 sites across the U.S. and Canada. ADNI has undergone three stages of 
recruitment each with differences in the imaging and biomarker analyses, these have been named ADNI-
1, ADNI-GO and ADNI-2. Collectively these protocols have recruited 1631 adults into the study consisting 
of age appropriate cognitively normal individuals, people with early or late MCI, and people with early 
AD. The follow up duration of each group is specified in the protocols for ADNI-1, ADNI-2 and ADNI-GO 
with 120 months as the maximum. Subjects were evaluated upon entry into the study, then at the 6 and 
12 month time points, and yearly after this. For up-to-date information, see www.adni-info.org.
Data cleaning
The dataset of the medical history (RECMHIST.csv), recurrent medicines (RECCMEDS.csv) and patient 
summary data (ADNIMERGE.csv) were downloaded on the 3rd of May 2018. To allow for adjustment for 
relevant nuisance variables string search methods were applied to generate the explanatory variables of 
headaches, arthritis, smoking, cardiovascular pathology and diabetes, where necessary (supplement 
5.4). Cardiovascular pathology was defined as a subject diagnosed with hypertension or high cholesterol 
(supplement 5.4.2). Terms varied widely and spelling errors were present and so manual confirmation of 
correct identification was required. A similar process was required to identify recurrent oral 
administration of NSAIDs (supplement 5.2). Only oral administration was included because topical 
applications are not likely to reach relevant concentrations. The search terms required a mixture of 
pharmacological and brand names. While a range of NSAIDs were searched for only aspirin, ibuprofen, 
diclofenac, celecoxib and naproxen had sufficient numbers for analysis (supplement 5.2) and 
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6paracetamol was included as a mechanistically distinct pain-reliever with similar potencies and 
indications as NSAIDs. Individuals diagnosed as cognitively normal, MCI or AD were included in the 
study, those with no diagnosis but reported subjective memory concerns (SMC) were removed as the 
subjective nature of self-diagnosis may be a source of variability. 
Distribution selection
To investigate cognitive decline over time generalised linear mixed modelling (GLMM) was applied. The 
selection of distribution was thoroughly performed both prior and following model construction 
investigating numerous distribution families (supplement 7.4, 7.5, 8.4, 8.5). Using graphical evaluation 
and Akaike information criterion (AIC) to evaluate the appropriateness of the distribution family, the 
negative binomial model was found to be the optimal distribution for both the MMSE and ADAS scores. 
For the simplicity of the model, the MMSE score was converted from a count of correct answers with a 
maximum of 30 into a count of incorrect answers (supplement 7.3), this has the advantage of now 
having the same directional relationship with disease severity as the ADAS score, with higher values 
correlating with worse cognitive performance and greater disease severity. Negative binomial models 
are optimal for overdispersed Poisson (count) data, suggesting that MMSE and ADAS scores can be 
modelled as a count of errors (supplement 7.5 & 8.5). 
Model construction
Selecting parameterisation method
From the initial distribution analyses it was found that the variance was greater than the mean 
indicating that the data were over-dispersed as a Poisson model supporting the use of negative binomial 
models (supplement 7.5 & 8.5)(Bolker et al., 2011, Hardin et al., 2007). There are several 
parameterisation methods which describe the relationship between the mean and the variance in the 
negative binomial model (over-dispersion). The two most common (and the only methods available in 
the glmmadmb package on R version 3.5.1 (R Core Team) with RStudio version 1.1.453 (Fournier DA et 
al., 2012, Skaug H et al., 2013)) are the ‘nbinom1’ method, which assumes the variance = k × mean, and 
‘nbinom2’ method, which assumes the variance = mean (1 + mean/k). The latter is most commonly 
used, particularly in count datasets, and is derived from a Gamma/Poisson model of a heterogeneous 
relationship between variance and mean (Hardin et al., 2007). The former describes a simple 
proportional relationship between variance and mean and is less commonly used due to its 
inflexibility(Hardin et al., 2007). Optimal parameterisation method was investigated using AIC and log-
likelihood both prior to, and following, the construction of the full models and the ‘nbinom1’ 
parameterisation was selected (supplement 7.6 & 8.6). 
Building of initial main effect model
Building of the GLMMs followed the protocol outlined by Hosmer et al. (Hosmer et al., 2013). To 
construct the negative binomial GLMM models the package glmmadmb was used on R version 3.5.1 
with RStudio version 1.1.453 (Fournier DA et al., 2012, Skaug H et al., 2013). This package estimates 
parameters using the maximum likelihood method with the Laplace approximation to assess the 
marginal likelihood and provides coefficient summaries based on Wald approximations. The minimal 
model used had the explanatory variable of time (month) included as well as subject ID as a random 
effect (supplement 7.8 & 8.8). Then each biologically relevant explanatory variable was individually 
added to the minimal model and then compared against the minimal model using the log likelihood 
ratio test with p-value estimated using the Chi-squared distribution and AIC to investigate if the model 
was significantly improved by the inclusion of the variable (supplement 7.8 & 8.8). Relevant nuisance 
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7explanatory variables were first investigated, followed by pain-reliever use. These included ApoE4 
genotype, age, diagnosis (control, MCI or Alzheimer’s disease), gender, education level, vascular 
pathology, smoking, headaches, arthritis, diabetes and drug use (naproxen, celecoxib, diclofenac, 
aspirin, ibuprofen or paracetamol). All significant variables were then included in the model and their 
continued input into the model in the presence of the other explanatory variables was evaluated using 
the Wald approximation statistics, Log likelihood ratio tests and AICs (supplement 7.9-7.12 & 8.9-8.12). 
Variables that ceased to contribute significantly to the model were dropped and the final main effect 
model of all significant variables was then constructed with p<0.05 considered as statistically significant 
(supplement 7.12.8 & 8.12.8). Biologically relevant interaction terms were then investigated within the 
main effect model. 
Inclusion of biologically relevant two-way interaction terms
The inference of multivariable interaction terms becomes difficult, therefore, a common approach is to 
investigate only biologically relevant two-way interaction terms (Hosmer et al., 2013). Similar to the 
main effect analyses, each two-way interaction term was added to the main effect model in isolation 
(supplement 7.13 & 8.13). Model was again assessed with the log likelihood ratio test and AIC values 
(supplement 7.13 & 8.13). A final model was constructed including all significant interactions (p<0.05) 
and Wald approximation statistics were scrutinized for non-significant coefficients (supplement 7.14 & 
8.14). Each interaction was then dropped in isolation from the model and compared against the full 
model including the variables that were dropped as main effect terms. The worsening of the model was 
assessed with the log likelihood ratio test and AIC values (supplement 7.14-7.17 & 8.14-8.17). 
Covariance matrices were constructed of the final model and no substantial multicollinearity was found 
between included explanatory variables (supplement 7.22 & 8.22). The full model was then tested with 
time (month) treated as a factor (as opposed to a continuous numerical variable) and years in education 
treated as a continuous numeric variable (rather than being grouped into education levels of early, 
middle, tertiary and post-graduate) (supplement 7.18-7.19 & 8.18-8.19). Treating month as a factor 
introduced a substantial increase in the degrees of freedom into the model (supplement 7.18 & 8.18), 
which resulted in levels of the models with insufficient data to stabilize the model resulting in issues of 
model convergence, even when more simple models with fewer explanatory variables were attempted. 
Treating years in education as a numeric variable worsened model fit; this is probably due to the lack of 
correlation between numerical years and the (log) dependent variable (supplement 7.19 & 8.19). 
Coefficient plots were generated with Laplace approximated confidence intervals to allow a quick 
visualisation of the effects of significant explanatory variables on the modelled decline over time 
(supplement 7.15 & 8.15). The variance/covariance matrices were used to generate Laplace plots of 
modelled decline given different combinations of the significant explanatory variables (supplement 9). 
To address issues of drop-out from the study for any reason, the analyses was repeated over the 
timeframe of 48 months (which has limited drop-out). The results were largely unaffected, suggesting 
drop-out was not having a strong bias effect on the full timeframe analyses (supplement 7.18, 8.18). We 
used uncorrected p-values in the results to not limit the sensitivity of the study. The corrected p-values 
(Holm-Šídák) are reported in the supplements. Example cognitive decline plots are displayed in the 
results section, these relationships can be fully explored at this interactive website depicting cognitive 
decline: 
https://braininflammationgroup-universityofmanchester.shinyapps.io/Rivers-Auty-ADNI/
Final models for MMSE and ADNI
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8Below are the final models selected by the methods above for both MMSE and ADAS score.
MMSE decline ~ Time + Age (of participant) + Gender + Education level + Diagnosis (cognitive) + ApoE4 
genotype + Diclofenac use + Aspirin use + Education level x Time + Diagnosis x Time + ApoE4 genotype x 
Time + Gender x Time + Paracetamol use x Time + Diclofenac use x Time + (Patient ID as a random 
variable) 
ADAS decline ~ Time + Age (of participant) + Gender + Education level + Diagnosis (cognitive) + ApoE4 
genotype + Headache + Diclofenac use + Ibuprofen use + Education level x Time + Diagnosis x Time + 
ApoE4 genotype x Time + Gender x Time + Paracetamol use x Time + (Patient ID as a random variable)
Prevalence analysis
Baseline prevalence of AD was analysed with Chi-squared statistics and adjusted logistic regression. 
Stepwise logistic regression with AIC as the selection criteria on the confounding variables was 
performed to generate the base model. Each pain reliever was added to the model and the 
improvement was evaluated based on Log likelihood ratio tests. P-values were adjusted using Holm-
Šídák multiple comparison adjustment method (supplement 6.4.4).
Assumption check of residuals
The Pearson residuals were extracted and plotted against the explanatory variables grouped by 
individual ID. The ungrouped Pearson residuals were also plotted. No trends were observed for any 
explanatory variable, indicating the appropriateness of the negative binomial models (supplement 7.21 
& 8.21).
Data availability
For transparency and repeatability, the code and results of the complete analyses summarised in the 
manuscript are included in full in the supplemental material. The data for the analyses presented here 
are available through application to the ADNI data repository at www.adni-info.org.
Results
Baseline statistics
This study included 1619 individuals of whom 338 (21%) had AD, 560 (35%) had late mild cognitive 
impairment (LMCI), 306 (19%) had early mild cognitive impairment (EMCI) and 415 (26%) were 
cognitively normal (CN). The proportions of each cognitive diagnosis did significantly differ with pain-
reliever use (supplement 6.4.4). Celecoxib, diclofenac, ibuprofen, paracetamol, aspirin and naproxen use 
were all associated with a substantially reduced AD prevalence compared to the no pain-reliever group 
(table 1, fig. 1, supplement 6.4), this effect remained after adjusting for confounding variables 
(supplement 6.4.4). This corresponded to significantly different mean baseline ADAS and MMSE scores 
(table 1, supplement 6.4). Other baseline metrics were nominally similar including gender proportions, 
mean age, ApoE4 status, educational attainment and diabetes prevalence (table 1, supplement 6). 
Headache, arthritis and cardiovascular risk factors were elevated in the pain-reliever groups (table 1, 
supplement 6). This is unsurprising as these pain-relievers are indicated for these conditions. Arthritis 
prevalence was highest in more potent pain-reliever groups such as celecoxib and diclofenac (73% and 
77%, respectively), compared to 28% prevalence in the no pain-reliever group (table 1, supplement 
6.4.10). 
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9The Effect of NSAIDs on Cognitive Scores
Aspirin, ibuprofen, naproxen and celecoxib were not found to be associated with any significant change 
in cognitive decline as measure by MMSE or ADAS (table 2 & 3, fig 2, supplement 7.17 & 8.17). 
Paracetamol use was associated with significantly accelerated decline in both MMSE and ADAS scores, 
however, the effect size is of limited clinical relevance (table 2 & 3, fig. 2). Diclofenac was found to be 
the only NSAID which was associated with reduced cognitive decline as measured by the MMSE score 
(table 2 & 3, fig. 2), and this effect approached significance for the ADAS score (supplement 8.17) with 
clinically meaningful effect sizes (fig. 2). The effect of diclofenac on MMSE decline remained significant 
(p=0.039) after correcting for multiple comparisons (supplement 7.17). 
There was some evidence of a main effect of aspirin and ibuprofen being associated with slightly 
improved MMSE and ADAS scores, respectively (table 2 & 3, fig. 2, supplements 7.17 & 8.17). This 
suggests that their use is associated with a mild fixed positive effect on cognitive scores, but they were 
not associated with altered progression of cognitive decline (table 2 & 3, fig. 2, supplements 7.17 & 
8.17). Diclofenac was associated with a significant positive effect on ADAS scores when included in the 
model only as a main effect (table 2 & 3, fig. 2, supplement 7.17 & 8.17), however, this main effect was 
not significant once the interaction term with time was included, suggesting the predominate effect of 
diclofenac is on cognitive decline.
As expected, there were significant main effects and effects on progression conferred by cognitive 
diagnosis with AD and LMCI both having worse MMSE and ADAS values and accelerated decline (table 2 
& 3, fig. 3, supplements 7.16 & 8.16). However, EMCI was not associated with accelerated progression 
of cognitive decline compared to the CN diagnosis, suggesting EMCI has limited prognostic utility (table 
2 & 3, fig. 3, supplements 7.16 & 8.16).
Education level had a complex relationship with cognitive decline. Post-graduate level study was set as 
the reference level. All other education levels had worse cognitive performance as main effects, 
however, their progression slopes were less severe, with tertiary level education associating with the 
slowest progression (table 2 & 3, fig. 3, supplements 7.16 & 8.16). A simplified inference of this is that 
post-graduate level studies was associated with initial good performance in the cognitive tasks but 
faster decline compared to tertiary, secondary and early education levels (table 2 & 3, fig. 3, 
supplements 7.16 & 8.16).
Age did have a significant main effect on MMSE and ADAS scores associating with worse cognitive scores 
(table 2 & 3, fig. 3, supplements 7.16 & 8.16). However, there was no evidence that age was associated 
with altered progression (supplements 7.16 & 8.16).
ApoE4 genotype had a substantial gene dose main effect on MMSE and ADAS score associating with 
worse cognitive performance (table 2 & 3, fig. 3, supplements 7.16 & 8.16), as well as an association 
with substantially accelerated cognitive decline (table 2 & 3, fig. 3, supplements 7.16 & 8.16). 
There was no discernible significant association of cardiovascular risk factors, smoking or diabetes on 
MMSE or ADAS score as a main effect or altering progression, therefore, for model parsimony they were 
not included in the final models (supplements 7.16 & 8.16).
Discussion
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Here we used the innovative approach of negative binomial generalized linear modelling to analyse the 
association between pain-reliever use and cognitive decline in CN, MCI and AD individuals in the ADNI 
dataset. From this we found that, while pain-reliever use was associated with a lower prevalence of AD, 
there were no similarly positive associations with delayed cognitive decline, with the exception of 
diclofenac use. This is congruent with the decades of epidemiological evidence which suggests that 
NSAID use lowers the prevalence of AD (Breitner et al., 1995, Cote et al., 2012, Fischer et al., 2008, in 't 
Veld et al., 2001, Landi et al., 2003, Stewart et al., 1997, Szekely et al., 2008, Vlad et al., 2008) and the 
limited number of clinical trials which have found no effect of NSAIDs on disease progression 
(Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group, 2013, Green et al., 2009, 
Lyketsos et al., 2007, Pasqualetti et al., 2009, Scharf et al., 1999). This suggests that either the 
therapeutic window of pain-relievers of AD is pre-symptomatic, acting on the initiating mechanisms of 
cognitive decline and not the propagating mechanisms of AD, or there is a hidden variable which 
explains the lower prevalence of AD in pain-reliever users, for example healthy user bias (Shrank et al., 
2011). Our analysis supports the latter. Healthy user bias is common in epidemiological research, it is 
caused by the effect of healthier individuals seeking and using therapies such as pain-relievers, resulting 
in spurious associations of therapy use and reduced disease prevalence. Our prevalence analysis shows 
similar reductions in the proportion of AD diagnoses between all pain-relievers, even structurally and 
functionally dissimilar compounds such as aspirin (weak COX1 and COX2 inhibitor), celecoxib (potent 
COX2 inhibitor) and paracetamol (endocannabinoid modulator, unlikely to inhibit COX1 and 2 at 
physiological concentrations (Klinger-Gratz et al., 2018)). The similarity in effects on AD incidence, 
despite structural and functional difference supports the existence of a hidden variable such as the 
healthy user bias. Furthermore, individuals taking any of the investigated drugs at the beginning of the 
study were less likely to drop-out (due to very poor health, death or other). This again supports the 
healthy user bias conclusion, as healthier subjects were more likely to remain in the study. This 
alternative explanation of the epidemiological AD prevalence literature, is further supported by the 
placebo controlled AD Anti-inflammatory Prevention Trial (ADAPT) trial (2013), which investigated the 
effects of celecoxib or naproxen on AD incidence in 2528 cognitively normal elderly people and found no 
positive effects, suggesting that COX inhibition is ineffective even in the presymptomatic stages of the 
disease.
Unlike the other pain-relievers, diclofenac use was associated with a slower cognitive decline as 
measured by MMSE scores and approached significance with ADAS scores. Though not thoroughly 
researched, there is evidence that diclofenac is a promising avenue of therapeutic development for AD. 
Landi et al. (2003) performed a cross-sectional study of 2708 community dwelling elderly people. They 
utilized logistic regression on the proportions of those diagnosed with AD in each NSAID category and 
found that diclofenac had the greatest effect on risk of AD diagnosis with an odds ratio of 0.21 (95%CI of 
0.05 – 0.90). Similarly, in the present study, diclofenac had the lowest prevalence of AD of all pain-
relievers tested, suggesting a potential prophylactic effect, as well as the reported potential therapeutic 
effect on disease progression. Furthermore, a small underpowered clinical trial was performed by Scharf 
et al. (1999). This was a single centre trial recruiting mild to moderate AD patients defined by an MMSE 
of 11 to 25. A total of 41 patients were recruited and 24 were randomly allocated to the placebo group 
and 17 to the daily diclofenac treatment group and the patients were followed up for cognitive 
assessment after six months of treatment (Scharf et al., 1999). Due to the lack of power of the study and 
short time span, no strong inferences should be made, however, the trends largely concur with the 
Landi et al. (2003) study and the present study; the placebo group declined cognitively with a mean 
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MMSE score decline of -0.86 (SD 3.21) and an ADAS increase of 1.93 (SD 5.55), while the diclofenac 
MMSE score improved on average 0.41 (SD 2.69) and the ADAS stayed relatively stable with a slight 
increase of 0.25 (SD 4.5)(Scharf et al., 1999). Given that the other NSAIDs tested in clinical trials did not 
slow the progression of AD and were not associated with slower decline in the present study despite 
also being potent inhibitors of the COX enzymes, it is fair to hypothesise that any potential effects of 
diclofenac on AD are likely not through this mechanism of action. Unlike the other pain-relievers 
investigated in this research, diclofenac also inhibits the release of the inflammatory cytokine 
interleukine-1β (IL-1β) (26, supplement 1) by inhibiting the activation of the intracellular receptor NLRP3 
(Nod-like receptor family, pyrin domain containing 3). The NLRP3 receptor in microglia has been shown 
to be central to the neuroinflammatory response observed in mouse models of AD (Daniels et al., 2016) 
and inhibition of the NLRP3 receptor with similar compounds has been found to be therapeutic in 
several animal models of AD (Daniels et al., 2016, Dempsey et al., 2017). Furthermore, studies have 
found that the genetic deletion of this receptor completely abated the AD phenotype in mouse models 
(Dostert et al., 2008, Heneka et al., 2013). Therefore, NLRP3 inhibition may be the defining feature of 
diclofenac. However, it should be noted that only 30 subjects were diclofenac consumers with sufficient 
data for inclusion in the analysis. Therefore, any strong inference of efficacy should be avoided as future 
research is needed on this promising NSAID.
The results of the analyses presented here found substantial evidence for ApoE4 causing accelerated 
cognitive decline. The lipoprotein ApoE4 is a well-established risk factor for the development of AD 
(Szekely et al., 2008, Notkola et al., 1998, Cornelius et al., 2004). Several studies have also found that 
ApoE4 alleles are associated with accelerated cognitive decline and accelerated cortical tissue atrophy 
(Bartzokis et al., 2006, Lo et al., 2011, Mielke et al., 2011, Morra et al., 2009, Rawle et al., 2018, Tilvis et 
al., 2004, Whitehair et al., 2010, Young et al., 2014, Kim et al., 2017, Kanai et al., 1999, Vijayaraghavan 
et al., 2016). However, a limitation common in the existing literature is the use of multi-level linear 
modelling for non-Gaussian discrete cognitive scores (Kanai et al., 1999, Kim et al., 2017, Lo et al., 2011, 
Mielke et al., 2011, Rawle et al., 2018, Vemuri et al., 2014, West et al., 2008, Whitehair et al., 2010), 
therefore, the present study, with 744 individuals with at least one ApoE4 gene, investigating both ADAS 
and MMSE measures of cognitive decline and applying discrete distribution GLMM analyses with the 
negative binomial models, represents a robust and important contribution to the field.
Previous research has reported that NSAIDs only alter AD incidence in ApoE4 carriers, suggesting an 
interaction between the potential therapeutic mechanism of NSAIDs and the pathological mechanisms 
of ApoE4 . This was first reported in a thorough study by Szekely et al. (2008) who looked at AD 
incidence in 3229 elderly people during a 10 year period. They found that NSAID use was associated 
with a hazard ratio of 0.88 in non-ApoE4 carriers and 0.34 in ApoE4 carriers (compared to matched 
individuals). The present study investigated a three-way interaction of NSAIDs, ApoE4 genotype and 
time (month), and no significant effects were observed (supplement 7.20 & 8.20). This suggests that if 
the Szekely et al. finding is due to NSAID-ApoE4 interactions, and not hidden nuisance variables present 
in the analysis, then this therapeutic effect may only be useful for the prophylactic treatment to prevent 
AD in ApoE4 individuals and not effective in altering the progression of the disease.
Conclusion
The present study is a thorough investigation into the effects of NSAID and paracetamol use on AD and 
MCI cognitive decline. Also investigated were the effects of gender, smoking status, headaches, arthritis, 
diabetes, age, vascular pathology, ApoE4 genotype and education level. Due to the discrete nature of 
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the dependent variables MMSE and ADAS scores, GLMMs were investigated and the negative binomial 
distribution was found to be a robust approach which outperformed other models. Ibuprofen and 
aspirin use were associated with improved cognitive performance at baseline, however, neither were 
associated with an altered cognitive decline. Naproxen and celecoxib use were not associated with any 
significant alterations in cognitive performance and paracetamol use was associated with accelerated 
cognitive decline although this effect size was negligible. This suggests that NSAIDs and paracetamol are 
not promising therapeutics for altering the progression of cognitive decline in MCI and AD individuals. 
However, diclofenac use was associated with slower cognitive decline, and as this was the only NSAID to 
do so, this suggests that COX inhibition is not the likely mechanism of action. Therefore, the full 
interactome of diclofenac should be investigated for potential therapeutic avenues. Collectively, the 
present study found interesting future avenues of research particularly the effects of paracetamol and 
diclofenac on AD progression and improved the evidence for our existing understanding of factors which 
effect AD such as the ApoE4 genotype by applying innovative statistical methods. 
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Aspirin Celecoxib Diclofenac Ibuprofen Naproxen Paracetamol No analgesic Statistics
Diagnosis
 CN 247 (29%) 19 (30%) 14 (47%) 79 (31%) 52 (28%) 119 (30%) 99 (21%)
 EMCI 174 (20%) 13 (20%) 5 (17%) 55 (22%) 45 (24%) 75 (19%) 67 (14%)
 LMCI 302 (35%) 25 (39%) 8 (27%) 92 (36%) 68 (37%) 140 (35%) 165 (35%)
 AD 138 (16%) 7 (10%) 3 (10%) 29 (11%) 21 (11%) 66 (17%) 141 (30%)
Χ2 (18)=78.1
p<0.0001
ADAS 16.4 (9.0)*** 15.8 (8.3) ns 12.3 (8.5)* 15.0 (8.5)*** 15.4 (8.9) ns 16.2 (8.8)ns 19.7 (10.3)
Χ2 (6)=57.5
p<0.0001
MMSE 27.3 (2.6)*** 27.2 (2.6) ns 28.0 (2.4) ns 27.7 (2.2)*** 27.6 (2.4) ns 27.4 (2.5)ns 26.4 (2.8)
Χ2 (6)=48.7
p<0.0001
Gender
 Male 323 (38%) 31  (48%) 15 (50%) 117 (46%) 95 (51%) 204 (51%) 223 (47%)
 Female 538 (62%) 33 (52%) 15 (50%) 138 (54%) 91 (49%) 196 (49%) 249 (53%)
Χ2 (6)=29.5
p<0.0001
Age 74.3 (6.7) ns 73.4 (6.9)ns 75.22 (6.4)ns 72.7 (6.8)* 72.9 (7.1) ns 74.3 (7.2) ns 73.9 (8.1)
F (6)=3.7
P=0.001
ApoE4 
 -/- 467 (54%) 35 (54%) 18 (60%) 145 (57%) 102 (55%) 231 (58%) 236 (50%)
 +/- 305 (35%) 24 (38%) 10 (33%) 88 (35%) 67 (36%) 133 (33%) 184 (39%)
 +/+ 89 (10%) 5 (8%) 2 (7%) 22 (9%) 17 (9%) 36 (9%) 52 (11%)
Χ2 (12)=7.5
p=0.822
Education
 Primary 318 (37%) 21 (33%) 10 (33%) 83 (33%) 56 (30%) 128 (32%) 161 (34%)
 Secondary 251 (29%) 18 (28%) 11 (37%) 77 (30%) 59 (32%) 119 (30%) 126 (27%)
 Tertiary 166 (19%) 12 (19%) 3 (19%) 50 (20%) 40 (22%) 92 (23%) 92 (19%)
 Post-grad 126 (15%) 13 (20%) 6 (20%) 45 (18%) 31 (17%) 61 (15%) 93 (19%)
Χ2 (18)=15.7
p=0.613
Headache 67 (8%) 11 (17%) 4 (13%) 31 (12%) 20 (11%) 52 (13%) 33 (7%)
Χ2 (6)=19.2
p=0.004
Arthritis 342 (40%) 47 (73%) 23 (77%) 127 (50%) 98 (53%) 215 (54%) 132 (28%)
Χ2 (6)=19.2
P<0.001
Diabetes 92 (7%) 7 (7%) 4 (9%) 26 (7%) 21 (8%) 46 (7%) 33 (4.7%)
Χ2 (6)=6.9
p=0.330
Smoker 205 (24%) 17 (27%) 8 (27%) 71 (28%) 40 (22%) 107 (27%) 127 (27%)
Χ2 (6)=4.5
p=0.614
Cardiovascular 
risk factors 555 (64%) 44 (69%) 16 (53%) 158 (62%) 114 (61%) 273 (68%) 261 (55%)
Χ2 (6)=19.8
p=0.003
Total 861 64 30 255 186 400 472
Table 1: Baseline statistics of ADNI cohort by pain-reliever use. 
All data are in N (%) except for ADAS, MMSE or Age which are expressed as mean (SD). CN=cognitively normal, EMCI and LMCI = early and late mild cognitive 
impairment, AD=Alzheimer’s disease, ADAS= Alzheimer’s disease assessment scale, MMSE=mini-mental state examination. Statistical analyses are Chi-squared 
test for proportions, maximum likelihood generalised linear modelling for score data, or general linear modelling for parametric data.
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Table 2: Summary of the final negative binomial GLMM with MMSE failures as the dependent variable. 
MMSE Estimate Stand Error Z value p-value Statistics of inclusion
Intercept -0.588 0.063 -9.33 p <0.00001 -
Fixed effects
Diagnosis
 CN - - - -
 EMCI 0.708 0.066 12 p <0.00001
 LMCI 1.242 0.056 22.38 p <0.00001
 AD 2.11 0.062 33.9 p <0.00001
χ2 (3)=1147.2, 
p<0.00001
Gender
 Female - - - -
 Male 0.096 0.040 2.36 p =0.01806
χ2 (1)=2.2, 
p=0.138010
Age 0.018 0.003 6.96 p <0.00001 χ
2 (1)=48.2, 
p<0.00001
ApoE4 
 -/- - - - -
 +/- 0.121 0.042 2.84 p =0.00446
 +/+ 0.226 0.065 3.49 p =0.00048
χ2 (2)=60.6, 
p<0.00001
Education
 Primary 0.352 0.057 6.14 p <0.00001
 Secondary 0.362 0.056 6.5 p <0.00001
 Tertiary 0.2 0.050 4.04 p =0.00005
 Post-grad - - - -
χ2 (3)=47.4, 
p<0.00001
Aspirin -0.075 0.037 -2.02 p =0.04345 χ
2 (1)=4.0, 
p=0.045500
Paracetamol -0.093 0.045 -2.07 p =0.03882 χ
2 (1)=1.8, 
p=0.179712
Diclofenac 0.023 0.146 0.015 p =0.87712 χ
2 (1)=1.0, 
p=0.317311
Interaction with time (months)
Diagnosis
 CN - - - -
 EMCI -0.00332 0.0010 -3.18 p =0.00145
 LMCI 0.00286 0.0007 3.95 p =0.00008
 AD 0.00880 0.0014 6.12 p <0.00001
χ2 (3)=79.8, 
p<0.00001
Gender
 Female - - - -
 Male -0.00172 0.0006 -2.92 p =0.00355
χ2 (2)=8.4, 
p=0.003752
ApoE4 
 -/- - - - -
 +/- 0.00588 0.0006 9.52 p <0.00001
 +/+ 0.00777 0.0009 8.32 p <0.00001
χ2 (2)=120.6, 
p<0.00001
Education
 Primary -0.00250 0.0008 -3.06 p =0.00224
 Secondary -0.00226 0.0008 -2.79 p =0.00532
 Tertiary -0.00375 0.0007 -5.05 p <0.00001
 Post-grad - - - -
χ2 (3)=26.6, 
p<0.00001
Paracetamol 0.00129 0.0006 2.18 p =0.02928 χ
2 (1)=4.8, 
p=0.0284597
Diclofenac -0.00468 0.0016 -2.89 p =0.00380 χ
2 (1)=8.4, 
p=0.0037522
Shown are the maximum likelihood estimates with Laplace estimates of the standard error, Z- value and p-value from the 
Wald approximation, as well as, the significance of inclusion of the variable in the model evaluated using the log-likelihood 
ratio test chi squared. CN=cognitively normal, EMCI and LMCI = early and late mild cognitive impairment, AD=Alzheimer’s 
disease, ADAS= Alzheimer’s disease assessment scale, MMSE=mini-mental state examination.
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Table 3: Summary of the final negative binomial GLMM with ADAS score as the dependent variable. 
ADAS Estimate Stand Error Z value p-value Statistics of inclusion
Intercept 2.991 0.032 92.09 p <0.00001 -
Fixed effects
Diagnosis
 CN - - - -
 EMCI 0.357 0.035 10.18 p <0.00001
 LMCI 0.771 0.03 25.69 p <0.00001
 AD 1.248 0.035 35.84 p <0.00001
χ2 (3)=1124.4, 
p<0.00001
Gender
 Female - - - -
 Male 0.106 0.023 4.6 p <0.00001
χ2 (1)=7.4, 
p=0.006524
Age 0.0133 0.003 8.52 p <0.00001 χ
2 (1)=71.4, 
p<0.00001
ApoE4 
 -/- - - - -
 +/- 0.096 0.024 3.92 p <0.00001
 +/+ 0.149 0.039 3.86 p = 0.0011
χ2 (2)=63.6, 
p<0.00001
Education
 Primary 0.181 0.033 5.41 p <0.00001
 Secondary 0.148 0.032 4.66 p <0.00001
 Tertiary 0.105 0.028 3.72 p =0.00020
 Post-grad - - - -
χ2 (3)=26.2, 
p=0.00009
Headache -0.087 0.039 -2.23 p =0.02563 χ
2 (1)=5.0, 
p=0.025347
Paracetamol -0.035 0.026 -1.35 p =0.17759 χ
2 (1)=0.8, 
p=0.371093
Ibuprofen -0.093 0.030 -3.14 p =0.00170 χ
2 (1)=9.8, 
p=0.0017451
Diclofenac -0.224 0.080 -2.8 p =0.00518 χ
2 (1)=7.8, 
p=0.0052246
Interaction with time (months)
Diagnosis
 CN - - - -
 EMCI -0.00162 0.0004 -3.98 p =0.00007
 LMCI 0.00021 0.0003 0.74 p =0.46177
 AD 0.00448 0.0007 6.17 p <0.00001
χ2 (3)=65.4, 
p<0.00001
Gender
 Female - - - -
 Male -0.00210 0.0003 -8.22 p <0.00001
χ2 (2)=67.0, 
p<0.00001
ApoE4 
 -/- - - - -
 +/- 0.00298 0.0003 11.31 p <0.00001
 +/+ 0.00476 0.0004 10.61 p <0.00001
χ2 (2)=186.2, 
p<0.00001
Education
 Primary -0.00135 0.0004 -3.74 p =0.00019
 Secondary -0.00149 0.0003 -4.29 p =0.00002
 Tertiary -0.00214 0.0003 -6.91 p <0.00001
 Post-grad - - - -
χ2 (3)=50.6, 
p<0.00001
Paracetamol 0.00056 0.0003 -2.21 p <0.00001 χ
2 (1)=4.8, 
p=0.0284597
Shown are the maximum likelihood estimates with Laplace estimates of the standard error, Z- value and p-
value from the Wald approximation, as well as, the significance of inclusion of the variable in the model 
evaluated using the log-likelihood ratio test chi squared. CN=cognitively normal, EMCI and LMCI = early and 
late mild cognitive impairment, AD=Alzheimer’s disease, ADAS= Alzheimer’s disease assessment scale, 
MMSE=mini-mental state examination.
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Figure 1: At baseline, use of any pain-reliever was associated with lower prevalence of Alzheimer’s disease (AD) and a 
corresponding higher prevalence of cognitively normal (CN) diagnoses. A) Proportion of cognitive diagnosis between 
pain reliever groups. Dotted lines show proportion divisions of No pain-reliever group. B) Pearson residuals demonstrate 
the size and direction of the effect of pain-reliever use on cognitive diagnosis. C) Contribution analysis of the significant 
association of pain-reliever subgroup and cognitive diagnosis reveals little difference between pain-reliever and the 
largest contribution to the significant effect is the No pain-relief group having a higher prevalence of AD and a lower 
prevalence of CN, compared to the other groups. CN=cognitively normal, EMCI and LMCI = early and late mild cognitive 
impairment, AD=Alzheimer’s disease, ADAS= Alzheimer’s disease assessment scale, MMSE=mini-mental state 
examination.
Figure 2: The effect of pain-reliever use on predicted cognitive decline as measure by MMSE (i) and ADAS (ii) scores. 
These models show the predicted decline of a LMCI, Female 70 year old, and how this decline changes when pain-relief 
use is included in the model. Any NSAID use (A); Aspirin (B); Celecoxib (C); Diclofenac (D); Ibuprofen (E); Naproxen (F); 
Paracetamol (G); Lines are predicted value, shaded area are 95% CI. LMCI = late mild cognitive impairment, ADAS= 
Alzheimer’s disease assessment scale, MMSE=mini-mental state examination.
Figure 3: The effect of significant explanatory variables on predicted cognitive decline as measure by MMSE (i) and 
ADAS (ii) scores. These models show the predicted decline of a LMCI (except A), Female (except C), 70 year old, and how 
this decline changes when additional variables are included. Cognitive diagnosis was predictably the most influential 
variable, with Alzheimer’s disease (AD) and late mild cognitive impairment (LMCI) associated with rapid cognitive 
decline; early MCI (EMCI) and cognitively normal (CN) did not have appreciatively different rates of decline (A). ApoE4 
showed a very strong gene dose association with accelerated cognitive decline (B). Gender showed mild differences with 
males having faster cognitive decline (C). Education had variable effects on cognitive decline with tertiary level education 
associated with the slowest decline (D). Lines are predicted value, shaded area are 95% CI. 
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The therapeutic potential of non-steroidal anti-inflammatories (NSAIDs) in Alzheimer’s disease is a 
contentious issue due to the incongruence between epidemiological, preclinical and clinical 
research. Using innovative statistical methods, we demonstrate that while most NSAIDs did not slow 
the progression of cognitive impairment, diclofenac dramatically improved cognitive outcomes.   
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